# A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

> **NCT06143579** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- Potentially Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** FOLFOX-HAIC+Lenvatinib+Envolizumab

## Key facts

- **NCT ID:** NCT06143579
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2025-03-03
- **Final completion:** 2026-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06143579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06143579, "A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06143579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*